These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007 [TBL] [Abstract][Full Text] [Related]
5. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong. Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790 [TBL] [Abstract][Full Text] [Related]
6. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial. Schilling WHK; Jittamala P; Watson JA; Boyd S; Luvira V; Siripoon T; Ngamprasertchai T; Batty EM; Cruz C; Callery JJ; Singh S; Saroj M; Kruabkontho V; Ngernseng T; Tanglakmankhong N; Tubprasert J; Abdad MY; Madmanee W; Kouhathong J; Suwannasin K; Pagornrat W; Piaraksa N; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Potaporn M; Srisubat A; Loharjun B; Taylor WRJ; Chotivanich V; Chotivanich K; Imwong M; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ; Lancet Infect Dis; 2024 Jan; 24(1):36-45. PubMed ID: 37778363 [TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study. Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795 [TBL] [Abstract][Full Text] [Related]
8. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry. Salmanton-García J; Marchesi F; Koehler P; Weinbergerová B; Čolović N; Falces-Romero I; Buquicchio C; Farina F; van Praet J; Biernat MM; Itri F; Prezioso L; Tascini C; Vena A; Romano A; Delia M; Dávila-Valls J; Martín-Pérez S; Lavilla-Rubira E; Adžić-Vukičević T; García-Bordallo D; López-García A; Criscuolo M; Petzer V; Fracchiolla NS; Espigado I; Sili U; Meers S; Erben N; Cattaneo C; Tragiannidis A; Gavriilaki E; Schönlein M; Mitrovic M; Pantic N; Merelli M; Labrador J; Hernández-Rivas JÁ; Glenthøj A; Fouquet G; Del Principe MI; Dargenio M; Calbacho M; Besson C; Kohn M; Gräfe S; Hersby DS; Arellano E; Çolak GM; Wolf D; Marchetti M; Nordlander A; Blennow O; Cordoba R; Mišković B; Mladenović M; Bavastro M; Limongelli A; Rahimli L; Pagano L; Cornely OA Int J Antimicrob Agents; 2023 Oct; 62(4):106952. PubMed ID: 37582478 [TBL] [Abstract][Full Text] [Related]
9. Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19. Sutanto ST; Sinto R; Pasaribu A; Shakinah S Acta Med Indones; 2022 Oct; 54(4):638-644. PubMed ID: 36624705 [TBL] [Abstract][Full Text] [Related]
10. Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents. Gentry CA; Nguyen P; Thind SK; Kurdgelashvili G; Williams RJ J Infect; 2023 Mar; 86(3):248-255. PubMed ID: 36702309 [TBL] [Abstract][Full Text] [Related]
11. New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19. Atmar RL; Finch N Antimicrob Agents Chemother; 2022 Aug; 66(8):e0240421. PubMed ID: 35862759 [TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model. Lieber CM; Cox RM; Sourimant J; Wolf JD; Juergens K; Phung Q; Saindane MT; Smith MK; Sticher ZM; Kalykhalov AA; Natchus MG; Painter GR; Sakamoto K; Greninger AL; Plemper RK Nat Commun; 2022 Jul; 13(1):4416. PubMed ID: 35906230 [TBL] [Abstract][Full Text] [Related]
13. Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study. Spiliopoulou V; Ntanasis-Stathopoulos I; Malandrakis P; Gavriatopoulou M; Theodorakakou F; Fotiou D; Migkou M; Roussou M; Eleutherakis-Papaiakovou E; Kastritis E; Dimopoulos MA; Terpos E Viruses; 2023 Mar; 15(3):. PubMed ID: 36992413 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes. Bajema KL; Berry K; Streja E; Rajeevan N; Li Y; Mutalik P; Yan L; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Ioannou GN Ann Intern Med; 2023 Jun; 176(6):807-816. PubMed ID: 37276589 [TBL] [Abstract][Full Text] [Related]
15. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life. Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504 [No Abstract] [Full Text] [Related]
16. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections. Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022. Harrington PR; Cong J; Troy SB; Rawson JMO; O'Rear JJ; Valappil TI; McGarry Connelly S; Farley J; Birnkrant D MMWR Morb Mortal Wkly Rep; 2023 Dec; 72(51):1365-1370. PubMed ID: 38127674 [TBL] [Abstract][Full Text] [Related]
18. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015395. PubMed ID: 38032024 [TBL] [Abstract][Full Text] [Related]
19. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912 [TBL] [Abstract][Full Text] [Related]
20. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants. Wang Y; Zhao D; Chen X; Liu X; Xiao W; Feng L Influenza Other Respir Viruses; 2023 Feb; 17(2):e13095. PubMed ID: 36843224 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]